Moderna, Inc. (MRNA)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Moderna, Inc. (MRNA)
Company Performance

Current Price

as of Oct 11, 2024

$58.29

P/E Ratio

N/A

Market Cap

$21.85B

Description

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Metrics

Overview

  • HQCambridge, MA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerMRNA
  • Price$58.29+2.57%

Trading Information

  • Market Cap$21.85B
  • Float89.17%
  • Average Daily Volume (1m)5,599,568
  • Average Daily Volume (3m)4,769,259
  • EPS-$15.36

Company

  • Revenue$5.04B
  • Rev Growth (1yr)-29.94%
  • Net Income-$1.28B
  • Gross Margin35.27%
  • EBITDA Margin-548.55%
  • EBITDA-$1.32B
  • EV$38.38B
  • EV/Revenue7.61
  • P/EN/A
  • P/S4.33
  • P/B1.86
Documents
SEC Filings
8-K (2024-10-02)
8-K (2024-09-12)
8-K (2024-08-01)
8-K (2024-07-23)
8-K (2024-05-09)
8-K (2024-05-02)
8-K (2024-02-22)
8-K (2024-01-08)
8-K (2023-12-12)
8-K (2023-11-06)
8-K (2023-11-02)
8-K (2023-10-16)
8-K (2023-09-11)
8-K (2023-08-03)
8-K (2023-05-05)
8-K (2023-05-04)
8-K (2023-02-23)
8-K (2023-01-09)
8-K (2023-01-03)
10-Q (2024-08-01)
10-Q (2024-05-02)
10-Q (2023-11-03)
10-Q (2023-08-03)
10-Q (2023-05-04)
10-K (2024-02-23)
10-K (2023-02-24)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-02)
Earnings Report (2023-08-03)
Factset Street Account
StreetAccount Metrics Recap - Moderna Q3 Earnings ($76.20, 0.00) (2023-11-02T11:10:46Z)
StreetAccount Earnings Call Q&A Summary: Moderna Q3 ($ 66.97, -9.23) (2023-11-02T13:51:32Z)
StreetAccount Consensus Metrics Preview - Moderna Q3 Earnings ($74.07, 0.00) (2023-10-30T21:01:15Z)
Moderna upgraded to hold from reduce at HSBC ($71.23, 0.00) (2023-11-03T09:55:37Z)
Moderna to unveil its comprehensive AI and digital strategy at its second Digital Investor Event ($73.66, 0.00) (2023-11-08T12:11:55Z)
Moderna reports Q3 EPS ($9.53) ($76.20, 0.00) (2023-11-02T10:37:08Z)
Moderna releases slide presentation in connection with their Digital Investor Event ($73.66, 0.00) (2023-11-08T14:21:44Z)
Moderna initiated hold at Canaccord Genuity ($78.19, 0.00) (2023-11-28T21:13:40Z)
Moderna files for Health Canada review of its respiratory syncytial virus (RSV) vaccine, mRNA-1345 ($104.26, 0.00) (2023-10-05T13:03:24Z)
Moderna downgraded to sell from hold at Deutsche Bank ($76.20, 0.00) (2023-11-02T12:42:52Z)
Moderna announces first participant dosed in Phase 3 study of mRNA-1083 combination vaccine against influenza and COVID-19 ($78.64, 0.00) (2023-10-24T11:05:00Z)
Moderna announces agreement with Caris Life Sciences ($78.64, 0.00) (2023-10-24T10:32:25Z)
Follow-up: Moderna reports Q3 results; provides preliminary thoughts on 2024/2025 sales (earlier) ($76.20, 0.00) (2023-11-02T12:48:14Z)
European Patent Office declares Moderna patent invalid, says BioNTech - Reuters ($78.96, 0.00) (2023-11-21T11:08:56Z)
Factset
Factset Business Description
Wikipedia
Moderna,_Inc